Iranian herbal-marine medicine, MS₁₄, ameliorates experimental allergic encephalomyelitis

• Published in: Phytotherapy research 2008-08, Vol.22 (8), p.1083-1086
• Main Authors: Tafreshi, Azita Parvaneh, Ahmadi, Amrollah, Ghaffarpur, Majid, Mostafavi, Hossein, Rezaeizadeh, Hossein, Minaie, Bagher, Faghihzadeh, Soghrat, Naseri, Mohsen
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animal Feed; Animals; Apium graveolens - chemistry; Biological and medical sciences; Biological Products - chemistry; Biological Products - therapeutic use; Brain - drug effects; Brain - pathology; Demyelinating Diseases - drug therapy; Demyelinating Diseases - immunology; Demyelinating Diseases - pathology; Disease Models, Animal; Disease Progression; EAE; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - physiopathology; Female; General pharmacology; Hypericum - physiology; Intracranial Hemorrhages - drug therapy; Intracranial Hemorrhages - immunology; Intracranial Hemorrhages - pathology; Iran; Medical sciences; Mice; multiple sclerosis; Necrosis; Penaeidae - chemistry; Pharmacognosy. Homeopathy. Health food; Pharmacology. Drug treatments; traditional medicine
• ISSN: 0951-418X; 1099-1573
• DOI: 10.1002/ptr.2459

Multiple sclerosis is an inflammatory and demyelinating disease of the central nervous system which mainly affects young adults. To overcome wide spectrum troublesome symptoms of multiple sclerosis which affects the quality of life both in patients and their families, new drugs and remedies have been examined and offered. The preclinical beneficial effects of different medicines have mostly been examined in an animal model of multiple sclerosis called experimental allergic encephalomyelitis (EAE). In this study we have tested a traditionally used natural (herbal-marine) product called MS₁₄ in EAE mice. EAE mice were fed with MS₁₄ containing diet (30%) on the immunization day and monitored for 20 days. The results show that while clinical scores and therefore severity of the disease was progressive in normal-fed EAE mice, the disease was slowed down in MS₁₄-fed EAE mice. Moreover, while there were moderate to severe neuropathological changes in normal fed mice, milder changes were seen in MS₁₄ fed mice. Copyright © 2008 John Wiley & Sons, Ltd.